Apparatus for detecting advanced glycation Endproducts fluorescence of skin

An apparatus for detecting advanced glycation Endproducts (AGE) fluorescence spectrum of skin has been designed. Some of the AGE have special fluorescence. When the tissue of skin is illuminated with excitation light, fluorescence emmited by tissue is detected. The intensity of detected fluorescence is related with the concentration of tissue AGE, which can determine a tissue state of individual. The apparatus can scan exciation light, and also can scan fluorescence emitted by tissue. Because the detection is perfomed noninvasively, so the apparatus could be adapted for use conveniently. we make use of the system to detect the excitation spectrum. At the same time, the emission spectrum is also be detected on the skin of nondiabetic individual and diabetes respectively, the result of the experiment indicates that there are difference distinctly about 450nm between them. The patient can benefit from it to forecast and diagnose the state of illness such as diabetes, decrepitude, oxidative stress. etc conveniently.

[1]  T. Lyons,et al.  Role of Glycation in Modification of Lens Crystallins in Diabetic and Nondiabetic Senile Cataracts , 1991, Diabetes.

[2]  V. Monnier,et al.  Chromatographic Quantitation of Plasma and Erythrocyte Pentosidine in Diabetic and Uremic Subjects , 1992, Diabetes.

[3]  C van Ypersele de Strihou,et al.  Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. , 1997, Kidney international.

[4]  J. Baynes,et al.  N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. , 1995, Biochemistry.

[5]  M. Brownlee,et al.  Glycosylation products as toxic mediators of diabetic complications. , 1991, Annual review of medicine.

[6]  C van Ypersele de Strihou,et al.  Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. , 1996, Journal of the American Society of Nephrology : JASN.

[7]  V. Monnier,et al.  Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. , 1989, The Journal of biological chemistry.

[8]  V. Monnier,et al.  Aging of proteins: immunological detection of a glucose-derived pyrrole formed during maillard reaction in vivo. , 1989, The Journal of biological chemistry.

[9]  N. Nakamura,et al.  Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo. , 1996, Biochemical and biophysical research communications.

[10]  V. Monnier,et al.  Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline. , 1992, The Journal of clinical investigation.

[11]  C van Ypersele de Strihou,et al.  Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. , 1999, Kidney international.

[12]  A. Cerami,et al.  Structure of carbohydrate of hemoglobin AIc. , 1977, The Journal of biological chemistry.

[13]  I B Lamster,et al.  Hyperglycemia, glycoxidation and receptor for advanced glycation endproducts: potential mechanisms underlying diabetic complications, including diabetes-associated periodontitis. , 2000, Periodontology 2000.

[14]  Masayoshi Takeuchi,et al.  Detection of N epsilon-(carboxymethyl)lysine (CML) and non-CML advanced glycation end-products in the anterior horn of amyotrophic lateral sclerosis spinal cord. , 2002, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[15]  N. Nakamura,et al.  Immunochemical quantification of crossline as a fluorescent advanced glycation endproduct in erythrocyte membrane proteins from diabetic patients with or without retinopathy , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[16]  Peter Riederer,et al.  AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? , 2004, Biogerontology.

[17]  N Taniguchi,et al.  Glycoxidation in aortic collagen from STZ-induced diabetic rats and its relevance to vascular damage. , 1998, Atherosclerosis.

[18]  山口 満喜子,et al.  Immunochemical quantification of crossline as a fluorescent advanced glycation endproduct in erythrocyte membrane proteins from diabetic patients with or without retinopathy , 1998 .

[19]  M. Brownlee.  Glycation and Diabetic Complications , 1994, Diabetes.

[20]  Paul J Thornalley,et al.  Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine- and Nepsilon-(1-carboxyethyl)lysine-modified albumin. , 2002, The Biochemical journal.